Anaemia is a common, multifactorial complication in chronic heart failure associated with poor prognosis, and erythropoietin therapy may offer a potential therapeutic avenue.
Answers are grounded in this paper and cite their sources.
Supports anaemia evaluation in heart failure; leaves open erythropoietin efficacy pending randomized trials.
Anaemia has been found to be a common complication of chronic heart failure. It is associated with exercise intolerance and a poor prognosis, independent of conventional markers of heart failure severity and markers of renal dysfunction. Although the cause of anaemia complicating heart failure is not known, it is likely to be multi-factorial in many patients. Anaemia, when present, reduces oxygen delivery to the periphery. Correcting this may improve capacity. Erythropoietin therapy has a long history in the management of renal failure with complicating anaemia, and the first reports of the use of erythropoietin in heart failure are now coming through. This article will review what is known of the aetiology of anaemia in chronic heart failure and what may be possible for erythropoietic therapy to achieve in chronic heart failure.
No takes yet. Share an insight, caveat, or question.
Andrew J.S. Coats (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: